US Patent

US10350171 — Celecoxib and amlodipine formulation and method of making the same

Formulation · Assigned to Dexcel Ltd Israel · Expires 2038-06-14 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a formulation of celecoxib and amlodipine, specifically a composition with granules containing celecoxib and extragranulate amlodipine.

USPTO Abstract

Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.

Drugs covered by this patent

Patent Metadata

Patent number
US10350171
Jurisdiction
US
Classification
Formulation
Expires
2038-06-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Dexcel Ltd Israel
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.